Sunday, December 22, 2024
Advertisement
  1. You Are At:
  2. News
  3. India
  4. No recommendation on mixing Covid vaccines, govt tells Parliament

No recommendation on mixing Covid vaccines, govt tells Parliament

​The government on Tuesday informed the Parliament that no recommendation was made on mixing anti-coronavirus vaccines.   

Edited by: India TV News Desk New Delhi Published : Aug 03, 2021 16:46 IST, Updated : Aug 03, 2021 16:46 IST
Covid vaccines, covishield covaxin mixing vaccines, no recommendation, govt parliament rajya sabha r
Image Source : PTI/FILE IMAGE

No recommendation on mixing Covid vaccines, govt tells Parliament

The government on Tuesday informed the Parliament that no recommendation was made on mixing anti-coronavirus vaccines. 

"COVID-19 vaccines have been developed recently. Therefore, scientific evidence about mix and match studies of different vaccines is still evolving," Minister of State for Health Bharati Pravin Pawar said in a written reply before the Rajya Sabha on Tuesday. 

She said no recommendation has been made so far to mix the first and second doses of Covid vaccines by the National Technical Advisory Group on Immunization or the National Expert Group on Vaccine Administration for COVID-19.

There is no specific recommendation from the World Health Organization presently on mix and match of vaccines, the minister added.

READ MORE: CDSCO expert panel recommends nod to study on mixing doses of Covaxin, Covishield

She was responding to a question on whether one can mix first and second doses of COVID vaccines and administer them to people who need it and whether any studies have been carried out or is there any scientific evidence that such mixing would not have any adverse impact on people.

Last week, news agency PTI had reported quoting official sources that an expert panel of India's central drug authority recommended granting permission to the Christian Medical College (CMC) in Vellore for conducting a clinical trial of mixing of two COVID-19 vaccines -- Covaxin and Covishield. 

The panel also recommended giving approval to Bharat Biotech for carrying out a study on interchangeability of its Covaxin and the under-trial adenoviral intranasal vaccine candidate BBV154, but asked the Hyderabad-based firm to remove the word "interchangeability" from the study title and submit a revised protocol for approval.

READ MORE: Over 49 crore vaccine doses given to states, 3 crore still unutilised, says Centre

Advertisement

Read all the Breaking News Live on indiatvnews.com and Get Latest English News & Updates from India

Advertisement
Advertisement
Advertisement
Advertisement